PPH and XBI both sit within the healthcare universe, but they occupy different corners of it. PPH targets mature, global pharmaceutical companies with established revenue and dividend streams, while XBI tracks the more speculative, innovation-heavy biotechnology segment, where stock prices often hinge on clinical trial results and regulatory approvals. This ETF comparison matters now because interest-rate expectations, a busy M&A cycle, and shifting sector rotation are pulling pharma and biotech in different directions. Comparing their sector exposure, fund performance, and relative positioning helps investors decide whether they want stable large-cap drugmakers or diversified exposure to a high-growth, high-volatility biotech complex. I also checked this using Tickeron’s AI Screener to see how the two funds stack up on relative strength metrics.
PPH tracks the MVIS US Listed Pharmaceutical 25 Index, a market-capitalization-weighted benchmark of the 25 largest U.S.-listed pharmaceutical companies. The fund typically holds about 25 securities, making it far more concentrated than a broad healthcare ETF. Top positions have historically included LLY, JNJ, NVS, NVO, MRK, PFE, and ABBV, with MCK, AZN, and SNY also prominent. Notably, PPH is not a purely domestic fund: U.S. issuers have represented roughly 60% of assets, with meaningful exposure to Switzerland, the United Kingdom, Denmark, and Japan. Its expense ratio is 0.36%. As a passive, market-cap-weighted vehicle, PPH tilts toward mega-cap, cash-generative names and typically delivers a higher dividend yield than its biotech counterpart, reflecting its defensive, income-oriented character.
XBI tracks the S&P Biotechnology Select Industry Index, an equal-weighted benchmark drawn from the biotechnology segment of the broader S&P market universe. The fund holds roughly 150 to 170 positions, far more than PPH, and rebalances periodically to restore equal weighting — a structure that prevents any single company from dominating returns. Top holdings have historically included MRNA, AMGN, GILD, ABBV, BIIB, REGN, and EXEL, but each position generally stays below roughly 3% of assets. Exposure is effectively 100% biotechnology. The expense ratio is 0.35%. Because XBI equal-weights across the capitalization spectrum, it provides substantially more small- and mid-cap exposure than PPH, which translates into higher volatility but also broader diversification across drug-development platforms, modalities, and therapeutic areas. From what I see, this equal-weight approach is a key differentiator worth monitoring with tools like Tickeron’s AI Trend Prediction Engine.
Both funds operate in a healthcare landscape shaped by several overlapping forces. Interest-rate expectations remain a central driver: lower long-term rates tend to support the valuations of pre-revenue and early-stage biotech companies that dominate XBI, while PPH's mature cash-flow names are comparatively insulated. A robust M&A environment — large pharmaceutical firms using balance-sheet strength to acquire innovative biotech platforms — has been a recurring catalyst for XBI's smaller constituents. Regulatory and drug-pricing scrutiny in the U.S., along with patent-expiration cliffs at several large drugmakers, weigh on PPH's mega-caps. Meanwhile, the GLP-1 obesity-drug boom has historically lifted select PPH names such as LLY and NVO, though that momentum can be concentrated and sentiment-sensitive. The two funds thus respond to very different catalysts despite their shared healthcare label.
In recent weeks and over recent market cycles, PPH and XBI have exhibited sharply different performance signatures. PPH has generally behaved as a lower-beta, large-cap vehicle, moving more in line with broad defensive pharma trends and providing relative stability during risk-off stretches. XBI, by contrast, has shown wider swings, reflecting its tilt toward small- and mid-cap companies whose fortunes turn on binary clinical news, financing conditions, and deal flow. When risk appetite strengthens and rate expectations ease, XBI's equal-weighted biotech complex has tended to outperform; when investors favor safety and income, PPH's mega-cap, dividend-paying structure has provided more resilient relative positioning. Volatility, single-name concentration, and sector rotation are therefore the defining differences between the two, with XBI carrying meaningfully higher beta and PPH offering greater downside ballast.
In my view, tools like Tickeron’s AI Screener can help surface relative momentum and technical patterns between funds such as PPH and XBI without spending hours on manual analysis. It allows filtering by industry, volatility, and performance metrics to highlight which exposure might align better with current market conditions. I find this particularly useful when evaluating concentrated versus diversified healthcare plays.
Weighing structural diversification, cost efficiency, trend consistency, and sector momentum, Tickeron's AI would currently lean toward XBI. Its equal-weighted design spreads risk across more than 150 companies rather than concentrating it in a handful of mega-caps, reducing the single-name vulnerability that PPH carries through its outsized weighting to LLY. Although XBI's volatility is higher, that volatility has historically coincided with stronger upside participation during biotech upcycles, when M&A activity and improving rate expectations favor the segment. Costs are effectively equivalent, so the decision rests on exposure: a probabilistic, momentum-aware framework favors XBI's broader, innovation-driven profile over PPH's defensive concentration in the current environment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The 10-day RSI Indicator for PPH moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 instances where the indicator moved out of the overbought zone. In 31 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a move down at 82%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PPH as a result. In 62 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for PPH turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 36 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for PPH crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +0.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPH advanced for three days, in 282 of 343 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
PPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 252 of 297 cases where PPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows